PAR2 Pepducins in Atopic Dermatitis
PAR2 Pepducin-Based Suppression of Inflammation
and Itch in Atopic Dermatitis Models
Barr T., Garzia C., Guha S., Fletcher E., et al. Journal of
Investigative Dermatology. February 2019.
Targeting PAR2 with Pepducins
Mellisa S. Lee & Ethan A. Lerner. Journal of Investigative Dermatology. August 2018.
PAR2 Pepducins in NASH, Fibrosis & Inflammation
Targeting Liver Fibrosis with a Cell Penetrating Protease-activated Receptor-2 (PAR2) Pepducin
Shearer A.M., Rana R., Austin, K., et al. J Biol Chem. October 2016.
Interdicting protease-activated receptor 2-driven inflammation with cell-penetrating pepducins
Sevigny L.M., Zhang P., Bohm A., Lazarides K. et al.
Proc Natl Acad Sci USA. May 2011.
Phase 1 and Phase 2 Clinical Trials with a PAR1 Pepducin
PAR1 Pepducin Therapy Targeting Myocardial Necrosis in CAD and ACS Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study
Kuliopulos, A., Gurbel P.A, Rade, J.J. et al.
Atheroscler Thromb Vasc Biol. December 2020
Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects with Coronary Artery Disease
Gurbel P.A, Bliden K.P., Turner U.S., Gesheff M.G. et al.
Atheroscler Thromb Vasc Biol. January 2016
PAR2 Pepducins Suppress Pancreatitis
Michael ES, Kuliopulos A, Covic L, et al. Am J Physiol Gastrointest Liver Physiol. Mar 2013.
Pepducins and Cancer
Protease-Activated Receptor 1 as a Therapeutic Target in Breast, Lung and Ovarian Cancer: Pepducin Approach
Covic L & Kuliopulos A. Int. J. Mol Sci.
July 2018. DOI: 10.3390/ijms19082237